Binge-Eating DisorderCHRONO-BENCT04724668
The Role of the Circadian System in Binge Eating Disorder
A study testing Melatonin (3hrs before DLMO), Morning light version 1 and Morning light version 2 in people with Binge-Eating Disorder and Circadian Rhythm Disorders, run by University of Cincinnati at 1 site in United States.
Trial summary
Binge eating disorder (BED) shows prominent circadian features that suggest a delay in circadian phase, and preliminary evidence shows binge eating may be responsive to chronobiological interventions, implicating a circadian system dysfunction in its pathophysiology. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Binge-Eating Disorder, Circadian Rhythm Disorders
- What is being tested?
- Melatonin (3hrs before DLMO), Morning light version 1 and Morning light version 2
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 84 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jan 2021to 30 May 2025
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Binge Eating Disorder (BED) group inclusion criteria:
- Age 18-50 years, inclusive
- Female or male
- BMI ≥30 kg/m2
- Current BED diagnoses by Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria confirmed by Structured Clinical Interview (SCID-5)
- Moderate or severe BED (≥3 binge eating episodes/week in the past 14 days)
- No current pharmacological treatment for BED, or if receiving treatment dose stable for ≥ 2 months
- If receiving psychotherapy, intervention must be stable for ≥ 3 months and agree to continue during the study
- Other psychiatric disorders will be permitted as long as they are not more than moderate in severity
- Using an effective contraceptive method (participants of childbearing potential)
BED exclusion criteria:
- Current severe comorbid psychopathology (i.e; mania, severe major depressive disorder (MDD), psychosis)
- Current (past month) substance use disorder (caffeine and nicotine allowed)
- Chronic use of bright light therapy (BLT) or melatonin in the past month
- Current contraindication or history of melatonin allergy or non-tolerability;
- Current contraindication or history of BLT non-tolerability
- Significant risk of suicide according to Columbia-Suicide Severity Rating Scale (CSSRS) or clinical judgment, or suicidal behavior in the past year
- Routine shift work (night work) in the past month
- Travel across more than 1 time zone in the past two weeks
- Current treatment with medication known to affect the circadian system or melatonin measurements, including: B-blockers, hypnotic sedatives, anticoagulants, antidiabetes drugs, oral corticosteroids, and other immunosuppressant medication
- Current lesions or bleeding in the oral cavity, as it may alter DLMO measurements
- Clinically significant unstable medical conditions as judged by the clinician, including: seizure or neurodegenerative disorders, thyroid conditions, autoimmune disorders, and cardiovascular disease
- Pregnancy or breastfeeding
- Participation in a clinical trial in the past month
- Suspected intelligence quotient (IQ) <80
- Any other clinically relevant reason as judged by the clinician
Control group inclusion criteria:
- Age 18-50 years, inclusive
- Female or male;
- BMI ≥30 kg/m2
- No current or lifetime history of BED or bulimia nervosa diagnoses confirmed by SCID-5
- No current (past month) psychiatric diagnosis according to SCID-5, including substance use disorders (caffeine and nicotine allowed)
- No current psychiatric or psychological treatment, or if receiving treatment dose/intervention stable for ≥ 2 months
Control group exclusion criteria:
- Clinically significant unstable medical conditions as judged by the clinician, including: seizure or neurodegenerative disorders, thyroid conditions, autoimmune disorders, and cardiovascular disease
- Chronic treatment with BLT or melatonin in the past month
- Routine shift work (work at night) in the past month
- Travel across more than 1 time zone in the past two weeks
- Significant risk of suicide according to CSSRS or clinical judgment, or suicidal behavior in the past year
- Current treatment with medication known to affect the circadian system or melatonin measurements, including, B-blockers, hypnotic sedatives, anticoagulants, antidiabetes drugs, oral corticosteroids, and other immunosuppressant medication
- Current lesions or bleeding in the oral cavity, as it may alter DLMO measurements
- Pregnant or breastfeeding
- Participation in a clinical trial in the past month
- Suspected IQ<80
- Any other clinically relevant reason as judged by the clinician
Trial locations and contacts
1 site in 1 country.
United States1 site
Lindner Center of HOPE / University of Cincinnati
Mason, Ohio, 45040
About this study
Binge eating disorder (BED) shows prominent circadian features that suggest a delay in circadian phase, and preliminary evidence shows binge eating may be responsive to chronobiological interventions, implicating a circadian system dysfunction in its pathophysiology. What remains lacking, however, is comprehensive knowledge of the characteristics of circadian system dysfunction in BED, and whether this dysfunction represents a therapeutic target in BED. There is therefore a critical need to characterize circadian system dysfunction in BED, and evaluate it as a potential therapeutic target. Without such information, the understanding on the role of the circadian system in BED and its potential as a new therapeutic target will remain limited.
Read the detailed description
The overall objective of the research strategy will be to characterize circadian system dysfunction in BED and its potential as a therapeutic target. The central hypothesis is that a circadian system dysfunction (phase delay) plays a role in the pathophysiology of BED, and that advancing the circadian phase will improve BED symptoms. To attain the overall objectives, the following specific aims will be pursued in two phases:
Specific aim 1) To characterize circadian system dysfunction in BED (Phase 1). Circadian system function will be evaluated in 80 adult (18 to 50yrs) obese subjects, 40 with BED and 40 without BED as a control group matched by age, body mass index (BMI), and gender, during a two-week observational phase. Based on preliminary data, the working hypothesis is that DLMO (the primary outcome measure) and secondary circadian parameters (i.e., locomotor activity acrophase) will occur later in the BED group compared with the control group, and a later circadian phase will be associated with worse BED clinical features.
Specific aim 2) To evaluate circadian phase as a predictive biomarker for response to a chronobiological intervention and evidence of circadian system target engagement in BED (Phase 2). A mechanistic clinical trial with a 4-week double-blinded, randomized, sham/placebo controlled study design will evaluate the effect of a combination of morning lights+Melatonin/placebo on the circadian system and eating behavior on 40 BED subjects that complete phase 1. Subjects will be randomized to receive a combination of morning lights at usual wake time + Melatonin(3mg) or placebo (3hr before DLMO). Based on preliminary data, the working hypothesis is that a chronobiological intervention will induce a greater DLMO advance (primary outcome measure), greater decrease in binge eating days/week (secondary outcome measure), and change in exploratory metabolic outcomes. In addition, a later baseline DLMO (secondary outcome) will predict change in binge eating days/week and metabolic parameters in response to a chronobiological intervention.
- Conditions
- Binge-Eating Disorder, Circadian Rhythm Disorders
- Being tested
- Melatonin (3hrs before DLMO), Placebo (3hrs before DLMO), Morning light version 1, Morning light version 2
- Keywords
- Binge eating, Circadian
- Medical subject headings
- Binge-Eating Disorder, Chronobiology Disorders, Bulimia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Melatonin (3hrs before DLMO)Dietary supplement
Melatonin 3mg (3hrs before DLMO)
Placebo (3hrs before DLMO)Dietary supplement
Placebo capsule (3hrs before DLMO)
Morning light version 1Device
Morning light version
Morning light version 2Device
Morning light version
| Study group | Role | What they receive |
|---|---|---|
| Morning light version+ Melatonin | Other | Morning light version and melatonin 3mg capsule (3hrs before DLMO) Receives: Dietary Supplement: Melatonin (3hrs before DLMO); Device: Morning light version 1 |
| Morning light version+ Placebo | Other | Morning light version and placebo capsule (3hrs before DLMO) Receives: Dietary Supplement: Placebo (3hrs before DLMO); Device: Morning light version 2 |
| Control group | No intervention | Adults with obesity without BED, only phase1 and did not receive intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase 1 Dim Light Melatonin Onset (DLMO)
Difference in mean DLMO (measured in hours) between subjects with binge eating disorder (BED) and control subjects without BED.
Measured: Phase 1 baseline (visit 0)
Phase 2 Dim Light Melatonin Onset (DLMO)
Differences in DLMO (measured in hours) change from baseline to endpoint between two intervention groups will be analyzed using an ANCOVA model with age as a covariate. Controls did not participate in the intervention (phase 2).
Measured: Phase 2 baseline (visit 0) to endpoint, on average one month.
Secondary outcomes (2)
Phase 1 MEQ
Difference in mean Morningness Eveningness Questionnaire scores (MEQ) between BED and control subjects without BED. MEQ score range 18 to 86, lower scores indicate more eveningness, higher scores indicate more morningness.
Measured: Phase 1 baseline (visit 0)
Phase 2 Binge Eating Days/Week
Differences in Binge eating days/week from baseline to endpoint between groups will be analyzed using an ANCOVA model with age as a covariate.
Measured: Phase 2 baseline (visit 0) to endpoint, on average one month.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2021
- Study start15 Jan 2021
- Primary completion30 May 2025
- Study completion30 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Binge-Eating DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The specific aims will be completed in a two-phase experimental approach. In the first phase (specific aim 1), subjects with obesity with BED (n=40) and without BED (n=40) will participate in a 2-week longitudinal study. In the second phase (specific aim 2), only BED subjects that complete phase 1 will rollover for a 4-week intervention study.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Cincinnati
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH), Lindner Center of HOPE
- Responsible party
- Principal investigator, Francisco Romo-Nava, University of Cincinnati
- Investigators
- Francisco Romo-Nava, MD, PhD, Principal investigator, University of Cincinnati/ Lindner Center of HOPE
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04724668
- Sponsor's protocol ID
- 2020-0345
- Other IDs
- 1K23MH120503-01A1
- Acronym
- CHRONO-BE
- Status last verified
- Jul 2026
- First submitted
- 20 Jan 2021
- Last updated
- 21 Aug 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: However, individual participant data may be shared with other researchers upon request.